Replimune finally wins approval, Q2 earnings wrap up, psychedelics stay in spotlight

0:00-19:01

After two rejections, Replimune has made it across the regulatory finish line with its twice-rejected therapy for advanced melanoma. Meanwhile, the last of the major pharmas, including Eli Lilly and Novo Nordisk, reported second quarter earnings, and psychedelics made headlines once again.

Publisher

BioSpace

Published

August 12, 2026

Duration

19 min

Format

Podcast

Category

Issues · Science

Source

RSS feed

B

BioSpace

@biospace

#replimunefinallywins #q2earningswrap #psychedelicsstay #lifesciences

The Nile